Why the study?
Diabetic cardiomyopathy causes late cardiac dysfunction with myocardial fibrosis linked to TGF-beta1 up-regulation, and the protective effect of 2-arachidonoylglycerol on diabetic cardiomyopathy required evaluation.
Does 2-Arachidonoylglycerol reduce myocardial fibrosis and improve cardiac function in a diabetic mouse model?
Population
Male C57BL/6 mice after 12 weeks of diabetic modeling
Comparison
2-AG (10 micro g/kg/day intraperitoneally) vs control
Design
Animal experimental study
Follow-up
4 weeks
Authors
Loading...
May attenuate diabetic cardiomyopathy in models; leaves open clinical translation of 2-AG or TGF-β/Smad targeting.
Does 2-Arachidonoylglycerol reduce myocardial fibrosis and improve cardiac function in a diabetic mouse model?
2-Arachidonoylglycerol attenuates myocardial fibrosis and improves cardiac function in diabetic mice by inhibiting the TGF-β1/Smad2/3 pathway.
Chen et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: